recurrent pericarditis - Health Topics
Markets Insider: Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider –– ... Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis Please provide your email address to receive an email when new articles are posted on . Acute and recurrent pericarditis require medical management to improve morbidity and quality of life.
Understanding the Context
Aspirin, ... CNN: Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) Rilonacept treatment resulted in a 96% reduction in risk of recurrent pericarditis events (primary efficacy endpoint: Hazard Ratio = 0.04, p<0.0001) Safety results consistent with FDA-approved label ... Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent Pericarditis (RHAPSODY) Recurrent pericarditis occurred in one fifth of patients with systemic lupus erythematosus (SLE), with higher recurrence rates observed in younger patients and those receiving oral prednisone therapy. Seeking Alpha: Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.
Image Gallery
Key Insights
Based on a successful ... Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Nasdaq: Kiniksa Pharmaceuticals to Initiate Phase 2/3 Clinical Trial of KPL-387 for Recurrent Pericarditis in 2025, Discontinues Abiprubart Development Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing Phase 1 ... Kiniksa Pharmaceuticals to Initiate Phase 2/3 Clinical Trial of KPL-387 for Recurrent Pericarditis in 2025, Discontinues Abiprubart Development Nasdaq: Kiniksa Pharmaceuticals Partners with Carly Pearce to Raise Awareness for Recurrent Pericarditis in New Campaign Kiniksa Pharmaceuticals has partnered with country music star Carly Pearce and NHL Hall-of-Famer Henrik Lundqvist to raise awareness about recurrent pericarditis, a chronic heart condition that is ... Kiniksa Pharmaceuticals Partners with Carly Pearce to Raise Awareness for Recurrent Pericarditis in New Campaign Credit: Getty Images A discussion on the new American Heart Association’s pericarditis initiative with Jimmy Kerrigan, MD.
Related Articles You Might Like:
how many teeth does an adult have ocala munroe regional hospital hipaa breach notification ruleFinal Thoughts
For the estimated 40,000 adults with recurrent pericarditis in the United ... Business Insider: Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis